Ghrelin: An Emerging Therapy for Heart Failure
Authors' conclusion
Ghrelin is a promising therapeutic option for HF, particularly as an inotropic agent with multifaceted benefits, including autonomic nervous system modulation, anabolic effects, and metabolic regulation. However, further trials are required to confirm its long-term efficacy and safety and assess whether its benefits can translate into reductions in hard clinical endpoints.
Study context
- Population
- Patients with heart failure (HF); HF models in preclinical studies4 RCTs, 1 open-label trial, 1 observational study
- Comparison
- Ghrelin therapy in HF
- Outcome
- Cardiac output with acute ghrelin in HF
Methodological detailsclinical and preclinical evidence, PubMed and Cochrane Library searched up to September 15, 2024; 247 records; 4 RCTs, 1 open-label trial, 1 observational study and key preclinical studies included
- Clinical and preclinical evidence
- PubMed and Cochrane Library searched up to September 15, 2024; 247 records; 4 RCTs, 1 open-label trial, 1 observational study and key preclinical studies included
Pooled result
As reported in the abstract
Significant improvements in cardiac output with acute ghrelin in HF patients
15% to 30%
Further pooled results
Preclinical findings
- Autonomic nervous system modulation, vasodilation, enhanced endothelial function, prevention of myocardial remodeling, reduced arrhythmogenic risk, increased muscle mass in HF models
Original publication
Ghrelin: An Emerging Therapy for Heart Failure. Clin Endocrinol (Oxf). Published 5 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →